Name | Adenosine A1 receptor activator T62 |
Description | Adenosine A1 receptor activator T62 is an allosteric enhancer of the adenosine A1 receptor, producing antinociception in animal models of acute pain and reducing hypersensitivity in models of inflammatory and nerve-injury pain[1][2][3]. |
Animal Research | Intrathecal T62 of Male SpragueDawley rats (250 g) after paw incision surgery with the dose of 0.3 μg, 0.5 μg, 1 μg, and 3 μg, produced a dose-dependent antihypersensitivity effect, with no effect on ambulation or activity level. The ED40 (95% confidence interval) for T62 was 0.77 (0.63-0.91) microg. |
In vivo | Intrathecal administration of the adenosine A1 receptor activator T62 (0.3-3 μg) in male Sprague-Dawley rats produces a dose-dependent antihypersensitivity effect without affecting ambulation or activity levels[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 75 mg/ml (257.03 mM)
|
Keywords | α2-adrenoceptors | P1 receptor | neuropathic | intrathecal | Inhibitor | inhibit | hypersensitivity | Enhancer | antihypersensitivity | allosteric | Adenosine Receptor | Adenosine A-1 receptor activator T62 | Adenosine A1 receptor activator T62 | adenosine |
Inhibitors Related | Theophylline monohydrate | Diphylline | Acefylline | Adenosine 5'-monophosphate monohydrate | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Adenosine antagonist-1 | Doxofylline | FK-453 |
Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |